Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - EPI Pharmaceuticals

Drug Profile

Research programme: cancer therapeutics - EPI Pharmaceuticals

Alternative Names: PG-11000 Series; PG-11093; PG-11100 Series; PG-11122; PG-11144; SL11217; SL11218; SL11231; SL11237

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellgate
  • Developer EPI Pharmaceuticals
  • Class Naphthoquinones; Polyamines; Porphyrins; Quinones
  • Mechanism of Action Apoptosis stimulants; Cell division inhibitors; Histone deacetylase inhibitors; Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (IV)
  • 14 Dec 2011 Progen Pharmaceuticals completes EPI Pharmaceuticals formation and transfers the epigenetic and cell proliferation assets to EPI
  • 25 Feb 2011 Progen's cancer therapeutics are still at the preclinical stage for Cancer in Australia
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top